Facinicline (free base)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319747

CAS#: 677306-35-3

Description: Facinicline (free base) is a partial agonist of the nicotinic alpha-7 (α7) receptor that was being co-developed by Roche for the oral treatment of Alzheimer's.


Price and Availability

Size
Price

5mg
Not available
50mg
Not available
500mg
Not available
5g
Ask price
50g
Ask price
Size
Price

10mg
Not available
100mg
Not available
1g
Ask price
10g
Ask price
100g
Ask price
Size
Price

25mg
Not available
200mg
Not available
2g
Ask price
20g
Ask price

Facinicline (free base) is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319747
Name: Facinicline (free base)
CAS#: 677306-35-3
Chemical Formula: C15H18N4O
Exact Mass: 270.1481
Molecular Weight: 270.336
Elemental Analysis: C, 66.64; H, 6.71; N, 20.73; O, 5.92


Synonym: Facinicline; RG-3487; MEM-3454; R-3487; RO-5313534; RG3487; MEM3454; R-487; RO5313534; RG 3487; MEM 3454; R 3487; RO 5313534

IUPAC/Chemical Name: (S)-N-(quinuclidin-3-yl)-1H-indazole-3-carboxamide

InChi Key: TXCYUSKWBHUVEP-CYBMUJFWSA-N

InChi Code: InChI=1S/C15H18N4O/c20-15(14-11-3-1-2-4-12(11)17-18-14)16-13-9-19-7-5-10(13)6-8-19/h1-4,10,13H,5-9H2,(H,16,20)(H,17,18)/t13-/m1/s1

SMILES Code: C1CN2CCC1[C@@H](C2)NC(=O)C3=NNC4=CC=CC=C43


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
677306-35-3(Facinicline Free Base)
677305-02-1(Facinicline HCl)


References

1: Umbricht D, Keefe RS, Murray S, Lowe DA, Porter R, Garibaldi G, Santarelli L. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology. 2014 Jun;39(7):1568-77. doi: 10.1038/npp.2014.17. PubMed PMID: 24549101; PubMed Central PMCID: PMC4023143.

2: Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, Xie W, Rowe WB, Ong V, Graham E, Terry AV Jr, Rodefer JS, Herbert B, Murray M, Porter R, Santarelli L, Lowe DA. RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther. 2011 Jan;336(1):242-53. doi: 10.1124/jpet.110.171892. PubMed PMID: 20959364.

3: Huang M, Felix AR, Kwon S, Lowe D, Wallace T, Santarelli L, Meltzer HY. The alpha-7 nicotinic receptor partial agonist/5-HT3 antagonist RG3487 enhances cortical and hippocampal dopamine and acetylcholine release. Psychopharmacology (Berl). 2014 May;231(10):2199-210. doi: 10.1007/s00213-013-3373-5. PubMed PMID: 24317442.

4: Kuang S, Zhang P, Dong EZ, Jennings G, Zhao B, Pierce M. Crystal form control and particle size control of RG3487, a nicotinic α7 receptor partial agonist. Int J Pharm. 2016 Jul 11;508(1-2):109-22. doi: 10.1016/j.ijpharm.2016.04.066. PubMed PMID: 27167333.

5: Hao Y, Tang J, Wang K. Development of Automated Patch Clamp Assay for Evaluation of α7 Nicotinic Acetylcholine Receptor Agonists in Automated QPatch-16. Assay Drug Dev Technol. 2015 Apr;13(3):174-84. doi: 10.1089/adt.2014.622. PubMed PMID: 25880723.

6: Hashimoto K. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker. Curr Pharm Des. 2015;21(26):3797-806. Review. PubMed PMID: 26044974; PubMed Central PMCID: PMC5024727.

7: Pohanka M. Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. Int J Mol Sci. 2012;13(2):2219-38. doi: 10.3390/ijms13022219. Review. PubMed PMID: 22408449; PubMed Central PMCID: PMC3292018.